9 recruiting, 4 completed, 4 unknown, 2 not yet recruiting. 9 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Not applicable, 1 Phase 4.
Follow HER2: new trials by email Literature Review of HER2 trials Research Report on HER2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 68Ga-XHER2 PET/CT for HER2 Assessment 68Ga-XHER2 PET/CT - Solid Tumor (Excluding CNS), HER2 | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 80 | 2026-10-22 | 2026-10-21 |
| First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations Almonertinib, Trastuzumab Rezetecan - Lung Cancer (NSCLC), EGFR Activating Mutation | Phase 2 | Not yet recruiting | Yongsheng Wang | 35 | 2026-09-09 | 2026-08-17 |
| Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy [68Ga]Ga-ABY-025 - Locally Advanced Cancer, Metastatic Cancer | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2026-04-16 | 2026-05-08 |
| Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics Urothelial Carcinoma (UC), HER2 | Enrolling by invitation | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 4000 | 2026-03-02 | 2026-03-06 | |
| MA-CRC-II-016 SHR-1811 SHR-A1811 & Bevacizumab injection, Chemotherapeutic Combinations - mCRC, HER2 | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 80 | 2025-12-30 | 2026-01-21 |
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors CGT4255 - Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer | Phase 1 | Recruiting | Cogent Biosciences, Inc. | 100 | 2025-12-30 | 2026-09-04 |
| Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC NSCLC (Advanced Non-small Cell Lung Cancer), HER2 | Recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 50 | 2025-08-12 | 2026-03-05 | |
| Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy Trastuzumab+Serplulimab - Urothelial Carcinoma, Biliary Tract Cancer | Phase 2 | Recruiting | Xiujuan Qu | 20 | 2025-07-15 | 2026-04-01 |
| Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment RC48 + Carboplatin - Ovarian Cancer, HER2 | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 20 | 2025-01-04 | 2025-12-16 |
| A Composite Assay for HER2-positive Early-stage Breast Cancer Management Breast Cancer Early Stage Breast Cancer (Stage 1-3), HER2 | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 180 | 2024-11-13 | 2025-01-08 | |
| Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer SOC plus trastuzumab and pembrolizumab - Biliary Tract Cancer, HER2 Gene Mutation | Phase 2 | Active not recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 24 | 2024-04-17 | 2026-03-27 |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers IAM1363 - HER2 Mutation-Related Tumors, HER2 | Phase 1 | Recruiting | Iambic Therapeutics, Inc | 383 | 2024-03-25 | 2026-09-09 |
| HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council Breast Neoplasms, Breast Cancer | Completed | AstraZeneca | 517 | 2024-03-05 | 2025-09-23 | |
| RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study Trastuzumab deruxtecan (DS-8201a) - Radiomic, Radiomics | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 500 | 2024-02-01 | 2025-06-22 | |
| RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression RC48, Tislelizumab - Non-Muscle Invasive Bladder Cancer, HER2 | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-08-05 | 2023-08-31 |
| Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy Disitamab Vedotin - HER2, Advanced Gastric Cancer | Unknown | Shen Lin | 306 | 2023-01-01 | 2022-12-16 | |
| Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression Disitamab Vedotin Combined With Fruquintinib - HER2, Colorectal Cancer | Phase 4 | Unknown | Zhongnan Hospital | 51 | 2023-01-01 | 2024-04-17 |
| Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System chemotherapy in combination with trastuzumab for arm1, chemotherapy in combination with trastuzumab for arm2, chemotherapy in combination with trastuzumab for arm3 - Targeted Therapy, HER2 | Phase 2 | Unknown | Shen Lin | 100 | 2017-07-01 | 2019-07-19 |
| Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China Breast Cancer, Neoadjuvant Therapy | Completed | Peking University First Hospital | 1077 | 2017-05-01 | 2020-09-28 | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Lucitanib - Breast Cancer, Metastatic Breast Cancer | Phase 2 | Terminated | Clovis Oncology, Inc. | 178 | 2014-09-09 | 2020-06-23 |
Showing 20 of 22. Sign in to see all of them.
Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (4) · Biliary Tract Neoplasms (3) · Carcinoma, Transitional Cell (2) · Colorectal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Neoplasms (2) · Stomach Neoplasms (2) · Brain Neoplasms (1) · Cholangiocarcinoma (1) · Disease (1) · Gallbladder Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Neoplasms by Site (16) · Neoplasms (15) · Breast Diseases (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Carcinoma (6) · Digestive System Diseases (6) · Digestive System Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Lung Diseases (4)
Drug Therapy (2) · Trastuzumab (2) · disitamab vedotin (2) · 26S proteasome non-ATPase regulatory subunit 13 (1) · Bevacizumab (1) · Carboplatin (1) · E-3810 (1) · HMPL-013 (1) · JPT1 protein, human (1) · Neoadjuvant Therapy (1) · RC48 antibody (1) · aumolertinib (1) · dacomitinib (1) · pembrolizumab (1) · tislelizumab (1)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Shen Lin (2) · Zhejiang Cancer Hospital (2) · AstraZeneca (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Clovis Oncology, Inc. (1) · Cogent Biosciences, Inc. (1) · Gruppo Oncologico Italiano di Ricerca Clinica (1) · Iambic Therapeutics, Inc (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Peking Union Medical College Hospital (1) · Peking University First Hospital (1) · RenJi Hospital (1) · Seoul National University Hospital (1) · The First Affiliated Hospital of Xiamen University (1)
China (9) · Italy (4) · United States (4) · South Korea (2) · France (1) · Germany (1) · Ireland (1) · Kuwait (1) · Netherlands (1) · Qatar (1) · Saudi Arabia (1) · Spain (1) · United Arab Emirates (1) · United Kingdom (1)
Lin Shen, MD (1) · Lin Shen, Master (1) · Marcello Tiseo, MD, PhD (1) · Paolo Verderio, PhD (1) · Salah-Eddin Al-Batran, Prof. Dr. (1) · Serena Di Cosimo, MD, PhD (1) · Xingfei Yu, M.D. (1) · Yung-Jue Bang, MD, PhD (1)
PMID 26581547, PMID 33796452, PMID 34395277, PMID 35844029, PMID 36550683